Table 1.

Combination chemotherapy in the treatment of aggressive fibromatosis

Study	No. of patients	Chemotherapeutic agents	Response	Duration oftherapy	Follow-up
Weiss and Lackman 1989 [6]	8	vinblastine and methotrexate	2 CR, 5 PR, ÌMR	NR	NR
Okuno and Edmonson 2003 [7]	7	cyclophosphamide 600 mg/m2 and doxorubicin 60 mg/m2; mitomycin 8 mg/m2, doxorubicin 40 mg/m2, and cisplatin 60 mg/m2; ifosfamide 2,500 mg/m2 and etoposide 100 mg/m2	Objective disease regression 3 patients, clinical benefit 6 patients	3–12 months 2–8 cycles	3 months-15 years
Patel et al. 1993 [8]	9	doxorubicin 60–90 mg/m2 and dacarbazine 750–1,000 mg/m2	2 CR, 4 PR, 1 MR, 2 SD	5 cycles	28–253 months
Gega et al. 2006 [9]	7	doxorubicin 20 mg/m2 daily and dacarbazine 150 mg/m2 followed by meloxicam 10 mg/m2	3 CR	4 cycles	NR
Azzarelli et al. 2001 [10]	30	methotrexate 30 mg/m2 and vinblastine 6 mg/m2	12 PR, 18 SD	38 cycles	6–96 months
Tsukada et al. 1991 [11]	8	adriamycin 50 mg/m2 and cyclophosphamide 250 mg/m2 and vincristine 2 mg/m2 and 5-FU 275 mg/m2; adriamycin 50 mg/m2 and cyclophosphamide 250 mg/m2 and dacarbazine 250 mg/m2 or actinomycin D	2 CR, 1 PR	NR	NR
Weiss et al. 1999 [15]	17	methotrexate 50 mg parenterally once a week and vinorelbine 20 mg/m2 weekly	3 CR, 7 PR, 2 MR, 3 SD, 2 PD	NR	NR

Response evaluation according to Response Evaluation Criteria in Solid Tumours (RECIST): CR = complete response; PR = partial response; SD = stable disease; MR = minor response; PD = progressive disease; NR = not reported